ELOX

Eloxx Pharmaceuticals, Inc. (ELOX) ESG Analysis Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.2 (Moderate)

ELOX appears to have limited disclosed environmental intensity in the provided metrics, which reduces comparability but also limits evidence of peer-leading operational sustainability.

Zero reported R&D-to-revenue in the supplied data suggests a lighter innovation footprint than research-intensive peers, though this is not a direct environmental indicator.

No emissions, energy, water, or waste metrics were provided, so environmental positioning versus peers cannot be confirmed as stronger or weaker on core material factors.

Relative to peers, the available data indicates neither a clear environmental advantage nor a structurally worse footprint, leaving the score anchored at a moderate level.

Social

Score:

The provided dataset contains no workforce, safety, turnover, or product-responsibility disclosures, which materially limits assessment of ELOX’s social positioning versus peers.

Zero stock-based compensation to revenue may indicate lower dilution-related employee alignment complexity than some peers, but it does not evidence stronger labor practices.

Absent customer, clinical, or community impact metrics, social risk assessment remains incomplete and cannot support a stronger peer-relative score.

Compared with peers that disclose broader human-capital and stakeholder metrics, ELOX’s social profile is opaque rather than clearly advantaged.

Governance

Score:

The reported net debt-to-EBITDA of 7.58 suggests elevated balance-sheet pressure, which can constrain governance flexibility relative to less leveraged peers.

Zero stock-based compensation to revenue may indicate lower equity-based incentive complexity than peers, but it does not offset the leverage-related governance concern.

No board, audit, ownership, or controversy data were provided, limiting confirmation of stronger oversight practices against peer standards.

Relative to peers, the available information points to a governance profile that is acceptable but weakened by leverage and insufficient disclosure.

Overall Score

Score:

ELOX screens as broadly average versus peers because limited disclosure prevents evidence of structural ESG leadership, while leverage modestly weakens governance positioning.

Score Driver: Insufficient ESG Disclosure, Combined With Elevated Leverage, Is The Decisive Factor Limiting Peer-Relative Positioning.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Eloxx Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →